Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034281 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
A Phase 1 study of Breast Neoplasm and Pancreatic Neoplasm, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 4
- Study locations
NCT00034281 is a Phase 1 study of Breast Neoplasm and Pancreatic Neoplasm that has completed, run by Takeda. The registered enrollment target is 16 participants, below the 162-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT00034281, a Phase 1 study of Breast Neoplasm and Pancreatic Neoplasm, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to investigate a safe dose of TAK-165, once daily (QD), in patients with HER2-tumor expression.
Conditions Studied
Interventions
- DRUG TAK-165
Study Locations (4)
Texas
- The Institute for Drug Development - San Antonio
- Brooke Army Medical Center/Drug Development Unit - San Antonio
- South Texas VA, Audie Murphy Division - San Antonio
Arizona
- Arizona Cancer Center - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2002-06 |
| Est. Completion | 2003-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00034281
The ClinicalTrials.gov registry entry for NCT00034281 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 162-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (90% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Breast Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which TAK-165 is the first listed.
NCT00034281 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT00034281 about?
NCT00034281 is a clinical study titled "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2". The purpose of this study is to investigate a safe dose of TAK-165, once daily (QD), in patients with HER2-tumor expression.
What is the current status of trial NCT00034281?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2002-06. Estimated completion is 2003-09.
What conditions does trial NCT00034281 study?
This clinical trial studies the following conditions: Breast Neoplasm, Pancreatic Neoplasm, Lung Neoplasm, Ovarian Neoplasm, Renal Neoplasm.
What interventions are being tested in trial NCT00034281?
The interventions under investigation include: TAK-165 (DRUG).
Who is sponsoring clinical trial NCT00034281?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00034281 being conducted?
This trial has 4 study locations across Arizona, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
RECRUITING · Phase 1
-
[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
-
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
[18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy
COMPLETED · Phase 1
-
Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.